Coral Laboratories Ltd

On 03-Dec, Coral Laboratories Ltd witnessed a notable decline in its share price, falling by 3.12% to close at ₹472.55. This drop reflects ongoing challenges for the stock, which has underperformed both its sector and the broader market benchmarks over recent periods.

As of November 17, 2025, Coral Labs is considered undervalued with a PE ratio of 10.25 and an EV to EBIT of 5.62, significantly lower than its expensive industry peers, suggesting potential for recovery despite a challenging year with a -40.17% stock return.

Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr during the same period.

As of November 13, 2025, Coral Labs is considered a very attractive investment with strong valuation metrics, including a PE ratio of 9.66 and a Price to Book Value of 0.89, despite a year-to-date stock performance of -34.52%, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab.

As of November 12, 2025, Coral Labs is considered undervalued with a PE ratio of 10.04 and strong ROCE of 24.89%, despite a year-to-date stock performance of -31.95%, making it an attractive investment compared to its more expensive peers like Sun Pharma and Divi's Lab.

As of November 3, 2025, Coral Labs. is considered very attractive due to its undervalued status, highlighted by a PE Ratio of 9.59 and strong growth potential indicated by a PEG Ratio of 0.00, despite recent stock performance lagging behind the Sensex.

As of October 30, 2025, Coral Labs is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 9.83, an EV to EBITDA of 4.40, and a Price to Book Value of 0.90, all significantly lower than its peers, indicating it remains a compelling investment opportunity despite recent underperformance against the Sensex.

As of October 28, 2025, Coral Labs. is considered very attractive due to its undervalued status, with strong financial ratios like a PE of 9.46 and an EV/EBITDA of 4.01, significantly lower than peers like Sun Pharma and Divi's Lab, despite a year-to-date stock performance lagging behind the Sensex.

As of 28-Oct, Coral Laboratories Ltd's stock price is Rs 489.35, down 2.12%, and has underperformed its sector. The stock has declined significantly year-to-date by 35.85%, contrasting with the broader market's positive performance.

Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales increasing from 78.12 Cr to 115.01 Cr and operating profit rising from 3.81 Cr to 26.24 Cr, while maintaining a stable financial position. Despite a negative cash flow trend, net cash inflow improved, indicating better cash management.

As of October 27, 2025, Coral Labs is considered an attractive investment with a PE ratio of 9.67 and an EV to EBITDA of 4.23, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date return of -34.46%, while showing strong long-term growth potential with a 98.79% return over three years.

As of October 20, 2025, Coral Labs is undervalued with a PE ratio of 9.57 and strong financial metrics, making it a compelling investment opportunity despite a year-to-date stock performance lagging behind the Sensex.

Coral Labs has experienced significant growth in net sales and profitability from Mar'23 to Mar'25, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr, indicating potential cash management challenges.

Coral Labs has shown significant growth in net sales and profitability, with net sales reaching 115.01 Cr in March 2025, up from 83.66 Cr in March 2024. Despite challenges in cash flow, the company reported increased operating profit and earnings per share, indicating strong operational efficiency.

As of 06-Oct, Coral Laboratories Ltd's stock price is Rs 520.00, down 0.24%, with a significant decline from an intraday high of Rs 497. Despite a 4.04% increase over the past week, it remains down 31.83% year-to-date, underperforming compared to the Sensex's 4.67% gain.

As of October 3, 2025, Coral Labs is considered undervalued with a PE ratio of 10.09 and an EV to EBITDA of 4.67, indicating a favorable valuation compared to expensive peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -31.57% against the Sensex's 3.93%, while achieving a strong 3-year return of 96.50%.

As of 30-Sep, Coral Laboratories Ltd is priced at Rs 485.00, down 2.96%, and has underperformed its sector and the benchmark Sensex. The stock shows a bearish trend with significant declines over the year, reflecting poor financial performance and negative investor sentiment.

As of September 26, 2025, Coral Labs is considered very attractive with a PE ratio of 9.42 and significant undervaluation compared to peers, despite a year-to-date stock decline of 36.16%, making it a compelling investment opportunity at a price of 487.00.